In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Longitudinal qualitative research - Capturing the patient voice; enhancing patient centricity
Outcomes researchers Alexia Marrel and Sally Lanar share insights on longitudinal qualitative research - what it is, when and how it can be used and the key factors for success when using this type of research.
-
Nominations now open for ‘Company of the Year’ Award 2022
This article features commentary from CEO Steve Cutler about ICON being awarded 2021 Company of the Year.
-
A blended solution – how midsize pharmaceutical and biotech companies can optimise the delivery of their clinical trials
John Barry, SVP and Chief Strategy Officer of ICON’s Strategic Solutions Division, considers the benefits of a blended model that combines FSP scale and CRO project-based sourcing for mid-size pharmaceutical and biotech companies.
-
How real world evidence is impacting rare disease drug development
Will Maier, VP of Rare Diseases, shares how a more patient-focused approach to trials is leading to alternatives for randomisation.
-
Incorporating patient preference vital to study success
Jayne Galinsky, Senior Outcomes Researcher, shares the importance of learning and assessing patient preferences in clinical research.
-
Patient voice, empathy key to paediatric study design
Jacqui Whiteway, discusses the unique challenges involved in designing a study when the patients are young
-
The cross-over of statistical thinking and practices: A pandemic catalyst
This article focuses on what others could learn from good statistical practices in drug development and considers areas where drug development could benefit from some fresh thinking
-
Tech advances making decentralised trial growth possible
Dr. Isaac R. Rodriguez-Chavez discusses the technology advancements that are making decentralised trial growth possible.
-
Decentralised clinical trial transformations are ‘here to stay’
Dr. Isaac R. Rodriguez-Chavz discusses the various factors behind the DCT format's rapid rise and likely longevity in the drug development process.
-
Improving early phase oncology clinical trial design: A case study
Tim Clark, VP Drug Development Solutions and Alan Phillips, Sr. Director Biostatistics present a case study on the first in human Bayesian Optimal Interval design.
